Epicardial Radiofrequency Catheter Ablation in Patients With Brugada Syndrome
NCT: NCT05685134 · COMPLETED
Brief Summary
This randomized, sham-controlled, and blinded clinical trial aims to evaluate the effects of radiofrequency catheter ablation on the phenotypic expression of patients with Brugada syndrome. The main questions it seeks to address are: * What are the immediate effects of radiofrequency catheter ablation on cardiac electrophysiology? * Is substrate-directed radiofrequency catheter ablation safe for patients with Brugada syndrome? * Is substrate-directed epicardial radiofrequency catheter ablation effective in normalizing the electrocardiographic pattern and preventing life-threatening arrhythmic events? Researchers will compare the ablation group with the control group to determine if there are differences in clinical and invasive markers of the disease after one year of follow-up.
Frequently Asked Questions
What is Epicardial Radiofrequency Catheter Ablation in Patients With Brugada Syndrome?
Epicardial Radiofrequency Catheter Ablation in Patients With Brugada Syndrome is a clinical trial registered under NCT05685134. Current status: COMPLETED.
What is the status of NCT05685134?
The current status of NCT05685134 (Epicardial Radiofrequency Catheter Ablation in Patients With Brugada Syndrome) is: COMPLETED.
When did Epicardial Radiofrequency Catheter Ablation in Patients With Brugada Syndrome start?
Epicardial Radiofrequency Catheter Ablation in Patients With Brugada Syndrome started on 2020-11-03.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.